Trial Profile
Phase II trial assessing the efficacy and tolerability of L 759274 in patients with generalised anxiety disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2012
Price :
$35
*
At a glance
- Drugs L 759274 (Primary) ; Lorazepam
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Acronyms 019
- Sponsors Merck & Co
- 25 May 2012 New trial record
- 20 Mar 2012 Results published in the International Journal of Neuropsychopharmacology.